HCPCS C9600: Drug‑Eluting Intracoronary Stent Placement, Single Vessel
Commercial payers pay $11067 on average nationally for this procedure.
HCPCS Level II code C9600 describes percutaneous transcatheter placement of drug‑eluting intracoronary stent(s), with coronary angioplasty when performed, for a single major coronary artery or branch; this is an interventional cardiology procedure typically performed in an ambulatory surgery center or hospital catheterization lab and is billed as a percutaneous coronary intervention (PCI) for coronary revascularization.
For related coverage guidance, see recent payer policy updates: Cardiac Computed Tomography (CCT)/Coronary Computed Tomographic Angiography (CCTA), Cardiovascular Disease Risk Assessment, Biomarkers for Myocardial Infarction and Chronic Heart Failure.
Customize your policy alerts
Sign up for hcpcs C9600 policy alerts
Get alerted when payer policies referencing C9600 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial reimbursement for HCPCS C9600 centers around BUCA’s average commercial rate of $11,067.40, which serves as an aggregate benchmark for commercial arrangements. Blue Cross Blue Shield exhibits the highest median and mean levels, while Aetna and UnitedHealth Group show much lower medians and means; BUCA’s positioning near the mid-to-high commercial band suggests a market midpoint between lower-tier payers and Blue Cross Blue Shield’s elevated rates.
Dispersion measured by the interquartile range (P75–P25) is tightest for Aetna with a range of $414.30 ($780.00–$336.70) and widest for Blue Cross Blue Shield with a range of $7,632.70 ($18,715.50–$11,082.80). UnitedHealth Group has a large spread of $11,766.50 ($16,766.70–$5,000.50), while BUCA’s IQR is $7,020.00 ($14,738.70–$7,717.10). These differences indicate varying commercial volatility across payers.